Canadians Living with Primary Biliary Cholangitis (PBC) One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI® (seladelpar)

Canadians living with primary biliary cholangitis (PBC), a rare and chronic liver disease, are one step closer to accessing a new publicly funded treatment option. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for LYVDELZI (seladelpar), reaching an agreement on the terms for public reimbursement.